LNZ100 FDA Approval Status
Last updated by Judith Stewart, BPharm on Aug 14, 2024.
FDA Approved: No
Brand name: LNZ100
Generic name: aceclidine
Dosage form: Ophthalmic Solution
Company: LENZ Therapeutics, Inc.
Treatment for: Presbyopia
LNZ100 (aceclidine) is a parasympathomimetic miotic agent in development for the treatment of presbyopia.
- Presbyopia is a condition that occurs due to a loss of elasticity in the lens of the eye during the aging process. Symptoms include blurry near vision (trouble seeing things up close and needing to hold reading materials farther away to focus on them), eye strain, and headache.
- LNZ100 contains aceclidine, an acetylcholine receptor agonist that causes pupil contraction to create a pinhole effect that improves near vision.
- The submission of the New Drug Application for LNZ100 in the treatment of presbyopia was supported by positive data from the pivotal Phase 3 CLARITY study, where it was shown to achieve all primary and secondary near vision improvement endpoints.
Development timeline for LNZ100
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.